Diagnosing NAFLD in Diabetic Patients with circRNA CDR1as: An Analysis of Efficacy and Correlation with Glucose Metabolism

CircRNA CDR1as: NAFLD Diagnostic Biomarker in Diabetes

  • Jingjing Zhang State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia, Department of Nephrology, The First Affiliated Hospital of Xinjiang Medical University,Urumgi,Xinjiang, 830054,China.
  • Xinzhi Zhang Xinjiang Medical University,Urumgi,Xinjiang, 830054,China.
  • Shadike Apaer State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Shuo Zhang State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Guangyou Liang State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Qiang Dong State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Jinchuang Huang State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Tao Li State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
  • Xinling Cao State Key Laboratory of Pathogenesis, Prevention and Treatment of High IncidenceDiseases in Central Asia,Department of Liver Transplantation & Laparoscopic Surgery, The First AffiliatedHospital of Xinjiang Medical University, Urumgi,Xinjiang,830054. China.
DOI: https://doi.org/10.5937/jomb0-62874
Keywords: CircRNA CDR1as, Non-alcoholic fatty liver disease (NAFLD), Diabetes mellitus (DM), Diagnostic biomarker, Glucose metabolism disorders

Abstract


Objective: To explore the expression characteristics and diagnostic efficacy of circRNA CDR1as, as well as its correlation with glucose metabolism disorders in patients with diabetes mellitus (DM) complicated by non-alcoholic fatty liver disease (NAFLD), so as to provide a novel target for precision diagnosis and treatment.

Methods: From May 2024 to August 2025, 74 DM patients complicated by NAFLD (research group) and 71 patients with uncomplicated DM (control group) were included. Serum CDR1as levels were detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR), fasting insulin (FINS) by chemiluminescence, fasting blood glucose (FPG) by a blood glucose meter, and glycosylated hemoglobin (HbA1c) by high-performance liquid chromatography (HPLC). The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. The diagnostic efficacy of CDR1as was evaluated by receiver operating characteristic (ROC) curves, and the correlation between CDR1as and glucose metabolism indexes was analyzed.

Results: CDR1as was expressed at an elevated level (29.00% greater) in the research group than in controls (P<0.05). In diagnosing NAFLD in DM cases, CDR1as showed an area under the ROC curve (AUC) of 0.781 (sensitivity 64.86%, specificity 80.28%). In stratified analysis, CDR1as exhibited superiority in diagnosing moderate and severe steatosis (S2/S3), with AUCs of 0.829 and 0.878, respectively. HOMA-IR, FINS, FPG, and HbA1c, all of which were higher in the research group compared to controls (P<0.05), showed a positive correlation with CDR1as. Treatment induced a decline in CDR1as expression (P<0.05), with higher levels observed in patients with a poor prognosis versus those with favorable outcomes (P<0.05). According to ROC curve analysis, the AUC of CDR1as in predicting prognosis was 0.747, with 57.14% sensitivity and 84.78% specificity.

Conclusion: CDR1as is over-expressed in DM patients with NAFLD, which can serve as a novel biomarker to diagnose NAFLD and evaluate glucose metabolism disorders.

Published
2025/12/09
Issue
Ahead of print
Section
Original paper

Copyright (c) 2025 Jingjing Zhang, Xinzhi Zhang, Shadike Apaer, Shuo Zhang, Guangyou Liang, Qiang Dong, Jinchuang Huang, Tao Li, Xinling Cao

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.

Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.